How Anabolic-Androgenic Steroid Dosage Shapes Physical and Psychosocial Harms

Anabolic-androgenic steroid (AAS) use is associated with physical and psychological harms, yet the extent to which these outcomes vary by dosage remains unclear. Using data from Wave 3 of the World’s First Steroid Checking Trial, this study examined associations between weekly AAS dose and self-reported harms among 121 AAS consumers. Of 105 analysed products, 50% were underdosed, 32% correctly dosed, 8% overdosed, and 25% contained unexpected compounds. Participants reported typical weekly dosage and side effects after dissemination of laboratory testing results. Dosage was examined descriptively across six brackets and inferentially as <500 mg versus ≥500 mg per week. Higher weekly doses were associated with increased reporting of liver issues, sleep disturbances, skin conditions, injection-site redness/swelling, and breast changes among women. No dose-related associations emerged for psychological harms. Findings suggest increased AAS dosage may drive physical harms, while psychological harms may be more compound-specific, informing tailored harm-reduction responses.

Authors

Institutions

Publication Details

Journal
Journal of Drug Issues
Published
2026-11-12
DOI
https://doi.org/10.1177/00220426261504703
Primary Topic
Doping in Sports
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

How Anabolic-Androgenic Steroid Dosage Shapes Physical and Psychosocial Harms

Steph Reeve, Cameron Francis, Ross Coomber, Luke Thomas Joseph Cox et al.
Journal of Drug Issues
Doping in Sports
article

How Anabolic-Androgenic Steroid Dosage Shapes Physical and Psychosocial Harms

Steph Reeve, Cameron Francis, Ross Coomber, Luke Thomas Joseph Cox, Timothy M. Piatkowski, Geoff Davey, Madeline C. Harding, Monica Jane Barratt, Sarah L. Cresswell, Jason Ferris, Cheneal Puljević, Emma Kill, Benjamin Bonenti, Brooke Walters, Imran Khan, Alan White
article en

Abstract

Anabolic-androgenic steroid (AAS) use is associated with physical and psychological harms, yet the extent to which these outcomes vary by dosage remains unclear. Using data from Wave 3 of the World’s First Steroid Checking Trial, this study examined associations between weekly AAS dose and self-reported harms among 121 AAS consumers. Of 105 analysed products, 50% were underdosed, 32% correctly dosed, 8% overdosed, and 25% contained unexpected compounds. Participants reported typical weekly dosage and side effects after dissemination of laboratory testing results. Dosage was examined descriptively across six brackets and inferentially as <500 mg versus ≥500 mg per week. Higher weekly doses were associated with increased reporting of liver issues, sleep disturbances, skin conditions, injection-site redness/swelling, and breast changes among women. No dose-related associations emerged for psychological harms. Findings suggest increased AAS dosage may drive physical harms, while psychological harms may be more compound-specific, informing tailored harm-reduction responses.

Journal of Drug Issues
Griffith University (AU), Burnet Institute (AU), University of Liverpool (GB), The University of Queensland (AU), Curtin University (AU), Swansea University (GB), National Drug Research Institute (AU)
National Health and Medical Research Council
Good health and well-being
Doping in Sports
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon